N3-L-Leu-OH (BHA) - CAS 79410-33-6 Catalog number: BADC-01906

N3-L-Leu-OH (BHA) is an important intermediate in peptide synthesis, used for incorporating leucine, a branched-chain amino acid, into peptides. The BHA (benzhydrylamine) protective group on the amino group of leucine ensures selective deprotection during solid-phase peptide synthesis (SPPS), making it an ideal reagent for constructing complex peptides with high precision. The stability provided by the BHA protection allows for efficient incorporation of leucine residues into peptide sequences while maintaining control over the synthetic process.

One of the key applications of N3-L-Leu-OH (BHA) is in the synthesis of peptides that are involved in protein-protein interactions. Leucine, due to its hydrophobic side chain, is known to play a crucial role in stabilizing the tertiary structure of peptides and proteins. By incorporating N3-L-Leu-OH into peptides, researchers can design peptides that mimic or interact with specific protein domains, which is valuable in drug discovery, especially for targeting protein-protein interactions that are central to various diseases, such as cancer and autoimmune disorders.

Another significant application of N3-L-Leu-OH (BHA) is in the development of peptide-based drug delivery systems. Leucine residues contribute to the hydrophobicity and stability of peptides, which can be advantageous for developing peptides that are more resistant to proteolysis and degradation. By using N3-L-Leu-OH in the synthesis of peptide-drug conjugates (PDCs), researchers can create more stable and bioavailable peptides for targeted drug delivery. This has particular implications in cancer therapy, where peptide-drug conjugates can deliver cytotoxic agents directly to tumor cells, reducing side effects and improving efficacy.

N3-L-Leu-OH (BHA) is also valuable in the design of cyclic peptides. Leucine’s hydrophobic properties and ability to promote peptide folding make it an excellent choice for creating cyclic structures that are more stable and less prone to degradation. These cyclic peptides, which are often used as enzyme inhibitors, can be synthesized using N3-L-Leu-OH (BHA) to form highly stable and specific therapeutic agents. The unique stability of cyclic peptides makes them promising candidates for a wide range of applications, including cancer therapy and antimicrobial treatments.

Finally, N3-L-Leu-OH (BHA) is utilized in the design of peptide vaccines and therapeutic peptides. The hydrophobic nature of leucine enhances the ability of peptides to interact with lipid membranes, making them useful for vaccine delivery systems. Leucine-containing peptides can be incorporated into vaccine formulations to improve immune responses and enhance the stability of the vaccine. These peptides are being explored in the development of vaccines for cancer, infectious diseases, and autoimmune conditions, where the controlled release and targeting of antigens is critical for eliciting an effective immune response.